Genetically-delivered Bevacizumab for Treatment of Wet Age-Related Macular Degene

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$261,327.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
1R43EY023108-01
Award Id:
n/a
Agency Tracking Number:
R43EY023108
Solicitation Year:
2013
Solicitation Topic Code:
NEI
Solicitation Number:
PA12-088
Small Business Information
750 17TH ST NW, STE 1100, WASHINGTON, DC, 20006-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
829689608
Principal Investigator:
KARENKOZARSKY
(202) 577-4374
kkozarsky@regenxbio.com
Business Contact:
JAMESBROWN
(202) 778-2365
jbrown@regenxbio.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): The goal of this Phase I SBIR is the pre-clinical development of a novel gene-based delivery system for bevacizumab (anti-VEGF antibody) to treat wet age-related macular degeneration (AMD). The premise is based on: (1)the demonstrated efficacy of monthly intravitreal injections of the monoclonal bevacizumab in treating wet AMD that is accompanied by a high cost of drug and safety issues related to the requirements for frequent administration; and (2) our demonstration that intravitreal genetic delivery of bevacizumab with the adeno-associated virus (AAV) serotype rh.10 vector, AAVrh.10BevMab, provides long term protection from inappropriate VEGF-mediated retinal angiogenesis in mice. While efficacious, current therapy ofrepeated intravitreal administration of bevacizumab monoclonal therapy is associated with discomfort, significant risks and high cost and administration of this antibody leads to high peak levels that may be associated with toxicity and prolonged troughlevels that are sub-therapeutic. This SBIR contains the following specific aims and milestones: Specific Aim 1. Assess the hypothesis that intravitreal administration of AAVrh.10BevMab can express therapeutic levels of bevacizumab in the eye of non-human primates. The milestone is to achieve therapeutic levels of biologically active bevacizumab with practical AAV dosing in terms of volume and vector concentration. Specific Aim 2. Based on the dose established in Specific Aim 1, assess the hypothesis that intravitreal delivery of AAVrh.10BevMab is effective in inhibiting laser induced neovascularization in non-human primates. This will provide the final supporting efficacy data, using a standard animal model, to allow design of a pivotal toxicology study to support FDA filing. A Phase II application will be submitted to support the pre- IND process and the product development and clinical trial. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Age-related macular degeneration (AMD) is one of the leading causes of blindness. The prevalence of AMD in the United States is expected to increase to nearly 3 million by 2020. Existing treatment are effective in limiting the progression of the disease but are problematic in both cost of drug and the requirements for frequent administration by intravitreal injection with attendant safety problems. This proposal initiates th clinical development of a new experimental therapy which involves a one-time genetic delivery system using a vector that provides long termexpression of the drug which is potentially cheaper and safer.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government